Carson M Quinn1,2, Enock Kagimu2, Michael Okirworth2, Ananta S Bangdiwala3, Gerald Mugumya4, Prashanth S Ramachandran5, Michael R Wilson5, David B Meya2, Fiona V Cresswell6, Nathan C Bahr7, David R Boulware8. 1. School of Medicine, University of California, San Francisco, San Francisco, California, USA. 2. Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. 3. Department of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA. 4. Microbiology Laboratory, Kiruddu National Referral Hospital, Kampala, Uganda. 5. Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, California, USA. 6. Clinical Research Division, London School of Hygiene and Tropical Medicine, London, United Kingdom. 7. Division of Infectious Diseases, Department of Medicine, University of Kansas, Kansas City, Kansas, USA. 8. Division of Infectious Diseases, Department of Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Abstract
BACKGROUND: Tuberculous meningitis (TBM) has a high fatality rate, with inadequate diagnostic tests being a major contributor. The rollout of Xpert MTB/Rif and Xpert MTB/RIF Ultra (Xpert Ultra) have improved time-to-diagnosis with sensitivities similar to culture, yet test availability and sensitivity are inadequate. The TB lipoarabinomannan lateral flow assay (AlereLAM) offers ease of use, but its low sensitivity in cerebrospinal fluid (CSF) limits clinical utility for TBM. The Fujifilm SILVAMP TB LAM (FujiLAM) assay has excellent sensitivity in urine, but performance on cerebrospinal fluid is uncertain. METHODS: We conducted a prospective cohort study at Kiruddu National Referral Hospital in Kampala, Uganda, enrolling patients suspected to have TBM. CSF was tested using AlereLAM, Xpert Ultra, culture, and FujiLAM. Results were compared with 2 reference standards: probable and definite TBM or definite TBM alone by the uniform TBM case definition. RESULTS: Of 101 patients enrolled (95/101 HIV-positive), 34 had definite TBM and 24 had probable TBM. FujiLAM sensitivity on CSF was 52% (30/58) for definite or probable TBM compared with 55% (32/58) for Xpert Ultra. AlereLAM had lower sensitivity than FujiLAM in the subgroup of patients tested with both assays (14% [4/28] vs 50% [14/28]; P < .01). FujiLAM specificity was 98% (42/43) for patients without probable or definite TBM. CONCLUSIONS: FujiLAM showed higher sensitivity than AlereLAM, with sensitivity potentially approaching that of Xpert Ultra. FujiLAM could improve time-to-treatment-initiation, especially in settings where the more technical Xpert Ultra system might not be feasible. Large confirmatory studies are needed.
BACKGROUND: Tuberculous meningitis (TBM) has a high fatality rate, with inadequate diagnostic tests being a major contributor. The rollout of Xpert MTB/Rif and Xpert MTB/RIF Ultra (Xpert Ultra) have improved time-to-diagnosis with sensitivities similar to culture, yet test availability and sensitivity are inadequate. The TB lipoarabinomannan lateral flow assay (AlereLAM) offers ease of use, but its low sensitivity in cerebrospinal fluid (CSF) limits clinical utility for TBM. The Fujifilm SILVAMP TB LAM (FujiLAM) assay has excellent sensitivity in urine, but performance on cerebrospinal fluid is uncertain. METHODS: We conducted a prospective cohort study at Kiruddu National Referral Hospital in Kampala, Uganda, enrolling patients suspected to have TBM. CSF was tested using AlereLAM, Xpert Ultra, culture, and FujiLAM. Results were compared with 2 reference standards: probable and definite TBM or definite TBM alone by the uniform TBM case definition. RESULTS: Of 101 patients enrolled (95/101 HIV-positive), 34 had definite TBM and 24 had probable TBM. FujiLAM sensitivity on CSF was 52% (30/58) for definite or probable TBM compared with 55% (32/58) for Xpert Ultra. AlereLAM had lower sensitivity than FujiLAM in the subgroup of patients tested with both assays (14% [4/28] vs 50% [14/28]; P < .01). FujiLAM specificity was 98% (42/43) for patients without probable or definite TBM. CONCLUSIONS: FujiLAM showed higher sensitivity than AlereLAM, with sensitivity potentially approaching that of Xpert Ultra. FujiLAM could improve time-to-treatment-initiation, especially in settings where the more technical Xpert Ultra system might not be feasible. Large confirmatory studies are needed.
Authors: Stephen D Lawn; Andrew D Kerkhoff; Rosie Burton; Charlotte Schutz; Andrew Boulle; Monica Vogt; Ankur Gupta-Wright; Mark P Nicol; Graeme Meintjes Journal: BMC Med Date: 2017-03-21 Impact factor: 8.775
Authors: A Dorothee Heemskerk; Joseph Donovan; Do Dang Anh Thu; Suzaan Marais; Lidya Chaidir; Vu Thi Mong Dung; Chad M Centner; Vu Thi Ngoc Ha; Jessi Annisa; Sofiati Dian; Louise Bovijn; Nguyen Thi Hoang Mai; Nguyen Hoan Phu; Nguyen Van Vinh Chau; Ahmad Rizal Ganiem; Cao Thao Van; Ronald B Geskus; Nguyen Thuy Thuong Thuong; Rovina Ruslami; Graeme Meintjes; Reinout van Crevel; Robert J Wilkinson; Guy E Thwaites Journal: J Infect Date: 2018-09-12 Impact factor: 6.072
Authors: Tobias Broger; Bianca Sossen; Elloise du Toit; Andrew D Kerkhoff; Charlotte Schutz; Elena Ivanova Reipold; Amy Ward; David A Barr; Aurélien Macé; Andre Trollip; Rosie Burton; Stefano Ongarello; Abraham Pinter; Todd L Lowary; Catharina Boehme; Mark P Nicol; Graeme Meintjes; Claudia M Denkinger Journal: Lancet Infect Dis Date: 2019-05-30 Impact factor: 25.071
Authors: Tobias Broger; Mark P Nicol; Rita Székely; Stephanie Bjerrum; Bianca Sossen; Charlotte Schutz; Japheth A Opintan; Isik S Johansen; Satoshi Mitarai; Kinuyo Chikamatsu; Andrew D Kerkhoff; Aurélien Macé; Stefano Ongarello; Graeme Meintjes; Claudia M Denkinger; Samuel G Schumacher Journal: PLoS Med Date: 2020-05-01 Impact factor: 11.069
Authors: Fiona V Cresswell; Jayne Ellis; Enock Kagimu; Ananta S Bangdiwala; Michael Okirwoth; Gerald Mugumya; Morris Rutakingirwa; John Kasibante; Carson M Quinn; Kenneth Ssebambulidde; Joshua Rhein; Edwin Nuwagira; Lillian Tugume; Emily Martyn; Caleb P Skipper; Conrad Muzoora; Daniel Grint; David B Meya; Nathan C Bahr; Alison M Elliott; David R Boulware Journal: Open Forum Infect Dis Date: 2020-03-24 Impact factor: 3.835
Authors: Stephanie Bjerrum; Tobias Broger; Rita Székely; Satoshi Mitarai; Japheth A Opintan; Ernest Kenu; Margaret Lartey; Kennedy K Addo; Kinuyo Chikamatsu; Aurélien Macé; Samuel G Schumacher; Emmanuel Moreau; Maunank Shah; Isik Somuncu Johansen; Claudia M Denkinger Journal: Open Forum Infect Dis Date: 2019-12-21 Impact factor: 3.835
Authors: Fiona V Cresswell; Angharad G Davis; Kusum Sharma; Robindra Basu Roy; Ahmad Rizal Ganiem; Enock Kagimu; Regan Solomons; Robert J Wilkinson; Nathan C Bahr; Nguyen Thuy Thuong Thuong Journal: Wellcome Open Res Date: 2021-01-28